Clinical trials: High-risk Smoldering Multiple Myeloma
Smoldering Plasma Cell Myeloma
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
This pilot trial studies how well leflunomide works for the treatment of patients with high-risk smoldering plasma cell myeloma, for the delay of disease progression.
- Trial name
- NCT04370483
- Testing
- Leflunomide, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
The purpose of this study is to see what effects, good and/or bad, the combination of ixazomib and dexamethasone has on the patient and the smoldering multiple myeloma.
- Trial name
- NCT02697383
- Testing
- Ixazomib (MLN9708), Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Monoclonal Gammopathy, Smoldering Multiple Myeloma
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM). The drug involved in this study is: -Daratumumab
- Trial name
- NCT03236428
- Testing
- Daratumumab
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
High-risk Smoldering Multiple Myeloma
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of siltuximab compared with placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) in patients…
- Trial name
- NCT01484275
- Testing
- Siltuximab
- Where
- 40 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
Background: Smoldering multiple myeloma (SMM) is a condition that can lead to multiple myeloma, a type of blood cancer. In many high-risk cases, SMM can develop into multiple myeloma in less than 2 years.
- Trial name
- NCT01660997
- Testing
- MLN9708, Dexamethasone
- Sponsor
- National Cancer Institute (NCI)
Smoldering Multiple Myeloma
A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk…
- Trial name
- NCT03301220
- Testing
- Daratumumab SC: daratumumab + rHuPH20
- Where
- 163 sites in United States, Argentina and 22 more
- Volunteers
- 390 people
- Sponsor
- Janssen Research & Development, LLC
Smoldering Multiple Myeloma
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
- Trial name
- SPOTLIGHT (NCT06212323)
- Testing
- Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Utah
Multiple Myeloma
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Background: Multiple myeloma (MM) is a tumor in which malignant plasma cells accumulate in the bone marrow. It can cause organ damage and is not curable. Researchers want to see if a combination drug treatment can help.
- Trial name
- NCT04933539
- Testing
- Dexamethasone, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Smoldering Multiple Myeloma
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM).
- Trial name
- ASCENT (NCT03289299)
- Testing
- Carfilzomib, Lenalidomide, Daratumumab
- Where
- 10 sites in United States
- Volunteers
- 87 people
- Sponsor
- International Myeloma Foundation
Smoldering Multiple Myeloma
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
This study will assess the antimyeloma effects of BHQ880A in patients with smoldering multiple myeloma with high risk of progression to active multiple myeloma.
- Trial name
- NCT01302886
- Testing
- BHQ880
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with…
- Trial name
- LINKER-MGUS1 (NCT06140524)
- Testing
- Linvoseltamab
- Where
- 39 sites in United States, Belgium and 5 more
- Volunteers
- 116 people
- Sponsor
- Regeneron Pharmaceuticals
Smoldering Myeloma, Smoldering Multiple Myeloma
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.
- Trial name
- NCT02279394
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Dana-Farber Cancer Institute
Smoldering Plasma Cell Myeloma
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma.
- Trial name
- NCT05014646
- Testing
- Cholestyramine, Leflunomide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression
The primary objective is to evaluate when Revlimid and Dexamethasone treatment extend the time to progression to symptomatic MM in patients with smoldering MM.
- Trial name
- QUIREDEX (NCT00480363)
- Testing
- Maintenance with lower doses of lenalidomide and dexamethasone
- Where
- 13 sites in Spain
- Volunteers
- 120 people
- Sponsor
- PETHEMA Foundation
Smoldering Multiple Myeloma
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma.
- Trial name
- NCT02903381
- Testing
- Nivolumab, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
Smoldering Multiple Myeloma (SMM)
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
This study is researching an investigational drug called linvoseltamab ("study drug") in participants at high risk of developing Multiple Myeloma (MM), a group commonly labeled as High-Risk Smoldering Multiple Myeloma (HR-SMM).
- Trial name
- NCT05955508
- Testing
- Linvoseltamab
- Where
- 17 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma, Smoldering Multiple Myeloma
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
The goal of this clinical trial is to test the safety, tolerability, and efficacy of TG01 vaccination in patients with KRAS or NRAS mutation on codon 12/13 mutation who has multiple myeloma or high-risk smoldering multiple…
- Trial name
- NCT05841550
- Testing
- TG01
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Oslo University Hospital
Myeloma
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple…
- Trial name
- NCT05055063
- Testing
- Belantamab mafodotin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Smoldering Plasma Cell Myeloma
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading.
- Trial name
- NCT02603887
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Smoldering Plasma Cell Myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma.
- Trial name
- NCT03937635
- Testing
- Daratumumab, Dexamethasone, Lenalidomide
- Where
- 748 sites in United States, Puerto Rico
- Volunteers
- 288 people
- Sponsor
- ECOG-ACRIN Cancer Research Group